Biocev 1st Faculty of Medicine Charles University Vestec Czech Republic

Department of Hematology General Faculty Hospital Prague Czech Republic

Group of Molecular Mechanisms and Biomarkers International Agency for Research on Cancer Lyon France

Zobrazit více v PubMed

Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106: 4315–4321. PubMed PMC

Wasik AM, Priebe V, Lord M, Jeppsson-Ahlberg A, Christensson B, Sander B. Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma. Leuk Lymphoma 2015; 56: 1425–1431. PubMed

Cuneo A, Balboni M, Piva N, Rigolin GM, Roberti MG, Mejak C et al. Atypical chronic lymphocytic leukaemia with t(11;14)(q13;q32): karyotype evolution and prolymphocytic transformation. Br J Haematol 1995; 90: 409–416. PubMed

Amador-Ortiz C, Goolsby CL, Peterson LC, Wolniak KL, McLaughlin JL, Gao J et al. Flow cytometric analysis of lymphoid enhancer-binding factor 1 in diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol 2015; 143: 214–222. PubMed

Huskova H, Korecka K, Karban J, Vargova J, Vargova K, Dusilkova N et al. Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas. Int J Hematol 2015; 102: 441–450. PubMed

Gutierrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Ferminan E et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21: 541–549. PubMed

Ek S, Andreasson U, Hober S, Kampf C, Ponten F, Uhlen M et al. From gene expression analysis to tissue microarrays: a rational approach to identify therapeutic and diagnostic targets in lymphoid malignancies. Mol Cell Proteomics 2006; 5: 1072–1081. PubMed

Cornet E, Debliquis A, Rimelen V, Civic N, Docquier M, Troussard X et al. Developing molecular signatures for chronic lymphocytic leukemia. PLoS One 2015; 10: e0128990. PubMed PMC

Hartwig JH, Thelen M, Rosen A, Janmey PA, Nairn AC, Aderem A. MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin. Nature 1992; 356: 618–622. PubMed

Sundaram M, Cook HW, Byers DM. The MARCKS family of phospholipid binding proteins: regulation of phospholipase D and other cellular components. Biochem Cell Biol 2004; 82: 191–200. PubMed

Rohrbach TD, Shah N, Jackson WP, Feeney EV, Scanlon S, Gish R et al. The effector domain of MARCKS is a nuclear localization signal that regulates cellular PIP2 levels and nuclear PIP2 localization. PLoS One 2015; 10: e0140870. PubMed PMC

Amess B, Manjarrez-Hernandez HA, Howell SA, Learmonth M, Aitken A. Multisite phosphorylation of the 80 kDa (MARCKS) protein kinase C substrate in C3H/10T1/2 fibroblasts. Quantitative analysis of individual sites by solid-phase microsequencing. FEBS Lett 1992; 297: 285–291. PubMed

Yang Y, Chen Y, Saha MN, Chen J, Evans K, Qiu L et al. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma. Leukemia 2015; 29: 715–726. PubMed

Chen CH, Thai P, Yoneda K, Adler KB, Yang PC, Wu R. A peptide that inhibits function of myristoylated alanine-rich C kinase substrate (MARCKS) reduces lung cancer metastasis. Oncogene 2014; 33: 3696–3706. PubMed PMC

Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 2012; 11: 937–957. PubMed PMC